Home Biosimilar Antibodies Others CD markers Polatuzumab (Anti-CD79b)
For research use only. Not for use in humans.

Polatuzumab (Anti-CD79b)

Synonyms: B29， IGB

Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD.

Polatuzumab (Anti-CD79b)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD.

Product Details

CAS No. 2279068-37-8
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07638722 NOT_YET_RECRUITING Drug: Polatuzumab Vedotin|Drug: Zanubrutinib Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Nodal Marginal Zone Lymphoma; Refractory Splenic Marginal Zone Lymphoma SWOG Cancer Research Network 2026-10-03 PHASE2
NCT05283720 ACTIVE_NOT_RECRUITING Drug: Epcoritamab|Drug: Lenalidomide|Drug: Ibrutinib|Drug: R Non-Hodgkin Lymphoma Genmab 2022-06-14 PHASE2
NCT07654426 RECRUITING Drug: Dexrazoxane|Drug: Dexrazoxane placebo|Drug: Doxorubici Diffuse Large B-cell Lymphoma (DLBCL); Cardiotoxicity; Lymphoma Beth Israel Deaconess Medical Center 2026-08-31 PHASE2
NCT07714421 NOT_YET_RECRUITING Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Polatuzumab V Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; Primary Mediastinal Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma Jonsson Comprehensive Cancer Center 2026-12-08 PHASE1
NCT07184788 NOT_YET_RECRUITING Drug: Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxal Aggressive B-Cell Lymphoma Navy General Hospital, Beijing 2025-10-01 PHASE2
NCT07702851 NOT_YET_RECRUITING Drug: Polatuzumab vedotin, Glofitamab Diffuse Large B-cell Lymphoma Yonsei University 2026-09-01 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.